XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.1
CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Preferred Stock
Common Stock
Additional Paid-In Capital
Service Receivable
Accumulated Other Comprehensive Loss
Accumulated Deficit
Balance, beginning (in shares) at Dec. 31, 2019   61 8,594        
Balance, beginning at Dec. 31, 2019 $ 7,310 $ 0 $ 8 $ 217,172 $ (972) $ 0 $ (208,898)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based compensation 177     177      
Issuance of common stock upon exercise of warrants (in shares)     1,610        
Issuance of common stock upon exercise of warrants 1,456     1,456      
Preferred stock dividend (6)           (6)
Release of clinical trial funding commitment 293       293    
Net loss (4,089)           (4,089)
Sale of common stock and warrants (in shares)     800        
Sale of common stock and warrants 1,000     1,000      
Issuance of common stock upon vesting of restricted stock units (in shares)     7        
Balance, ending (in shares) at Mar. 31, 2020   61 11,011        
Balance, ending at Mar. 31, 2020 6,141 $ 0 $ 8 219,805 (679) 0 (212,993)
Balance, beginning (in shares) at Dec. 31, 2020   716 36,781        
Balance, beginning at Dec. 31, 2020 128,158 $ 1 $ 4 361,819 (2,171) 0 (231,495)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based compensation 268     268      
Issuance of common stock upon exercise of warrants (in shares)     771        
Issuance of common stock upon exercise of warrants 1,263     1,263      
Other comprehensive loss (67)         (67)  
Preferred stock dividend (6)           (6)
Release of clinical trial funding commitment 380       380    
Net loss (5,179)           (5,179)
Balance, ending (in shares) at Mar. 31, 2021   716 37,552        
Balance, ending at Mar. 31, 2021 $ 124,817 $ 1 $ 4 $ 363,350 $ (1,791) $ (67) $ (236,680)